📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-07 19:46
0 analysed today
0
Today
133,620
All-time analysed
40,132
Positive
6,284
Negative
79,384
Neutral
7,752
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
17 announcements match the current filters (relevance ≥ 5).
66% PAT Growth in Q1 FY27; GPT Healthcare Reports 18.2% Revenue Increase
GPT Healthcare reported a strong Q1 FY27 with total income rising 18.2% and PAT surging 66% YoY. While overall network occupancy stood at 45.5%, mature hospitals maintained a healthier 58.07%, reflecting the initial ramp-up phase of the newly commissioned Raipur facility which reached 17% occupancy. ARPOB improved to ₹42,350, driven by a shift toward high-end tertiary care and robotic surgeries. Management expects the Dumdum facility to reach 70% occupancy by Q3 FY27 and is targeting approximately 10 liver transplants annually at the Raipur unit.
Confidence: HIGH
What changedThe company has transitioned from a pure capacity addition phase to an operational ramp-up phase, specifically showing traction in robotic surgeries and organ transplants.
Why it mattersThe significant jump in PAT relative to revenue suggests improving operational leverage and a better case mix, which is critical for a mid-sized hospital chain to improve its 16.8% OPM.
PAT Growth (YoY): 66%Revenue Growth (YoY): 18.2%Network ARPOB: ₹42,350Cash and Insurance Payer Mix: 90%Raipur Occupancy: 17%Mature Hospital Occupancy: 58.07%
📅 Short termThe stock may see positive interest due to the high PAT growth and successful clinical milestones like the first liver transplant in Raipur.
📈 Long termLong-term value depends on the Raipur facility reaching monthly breakeven (expected by month 13-14) and the successful commissioning of the Ranchi unit in FY28.
⚠ Risk flags
- Low occupancy at the new Raipur unit (17%) acting as a drag on overall margins
- Geographic concentration in West Bengal and Tripura
- Geopolitical issues impacting patient inflow from Bangladesh at the Agartala unit
Key Highlights
PAT increased by 66% YoY during Q1 FY27, significantly outpacing revenue growth.
Total income grew by 18.2% YoY, supported by a 31% revenue jump at the Howrah facility.
Average Revenue Per Occupied Bed (ARPOB) improved to ₹42,350 across the network.
Mature hospital occupancy (excluding Raipur) remained steady at 58.07%.
Raipur facility achieved NABH accreditation in a record 13 months with occupancy rising to 17% from 7% YoY.
👀 What to Watch
Monitor the occupancy ramp-up at the Raipur facility and the management's ability to sustain ARPOB growth through complex surgeries. Investors should also track the execution timeline for the Ranchi hospital planned for FY28.
GPT Healthcare Declares ₹1.50 Final Dividend at 37th AGM; Total FY26 Dividend at ₹2.50
GPT Healthcare concluded its 37th Annual General Meeting on August 6, 2026, where shareholders approved a final dividend of ₹1.50 per share. This brings the total dividend for FY25-26 to ₹2.50 per share, which is notable given the FY26 EPS of ₹2.08. The meeting also covered the adoption of FY26 audited financials (Revenue: ₹227.27 Cr, PAT: ₹17.05 Cr) and the re-appointment of several directors. Additionally, shareholders considered resolutions for remuneration and consultancy fees for three related-party medical professionals.
Confidence: HIGH
What changedThe company has finalized its dividend distribution for FY26 and obtained shareholder approval for its annual financial accounts and board composition.
Why it mattersThe total dividend of ₹2.50 per share represents a high payout ratio relative to the FY26 EPS of ₹2.08, signaling a strong commitment to returning cash to shareholders despite ongoing expansion plans in Raipur and Ranchi.
Final Dividend: ₹1.50 per shareTotal FY26 Dividend: ₹2.50 per shareDividend vs FY26 EPS: 120.19%Shareholder Attendance: 65.60%FY26 Revenue: ₹227.27 Cr
📅 Short termThe confirmation of the final dividend is likely to be viewed positively by retail investors in the coming days.
📈 Long termLimited structural impact as this was a routine AGM; however, the high dividend payout suggests management confidence in cash flows despite the capital-intensive nature of hospital expansions.
⚠ Risk flags
- Dividend payout exceeds FY26 earnings per share
- Multiple related-party remuneration approvals
Key Highlights
Final dividend of ₹1.50 (15%) declared, bringing total FY26 dividend to ₹2.50 per share
66 members attended the meeting, representing 65.60% of the company's shareholding
FY26 Audited Financial Statements adopted with a reported revenue of ₹227.27 Cr and PAT of ₹17.05 Cr
Shareholders voted on the re-appointment of Independent Directors Mr. Hari Modi and Dr. Tapti Sen
Approval sought for professional fees and remuneration for three related-party individuals (Dr. Mridul Tantia, Dr. Niharika Tantia, and Dr. Ghanshyam Goyal)
👀 What to Watch
Investors should monitor the final voting results to be published within 2 working days to confirm the approval of related-party remuneration and director re-appointments.
GPT Healthcare Q1 FY27: PAT Surges 65.7% YoY to ₹12.7 Cr with 20.4% EBITDA Margin
GPT Healthcare reported a strong start to FY27 with total income rising 18% YoY to ₹128.2 Cr. Profitability saw a significant boost as PAT jumped 65.7% YoY to ₹12.7 Cr, supported by EBITDA margins expanding 300 bps to 20.4%. While overall occupancy stood at 45.5% due to the new Raipur facility, mature hospitals maintained a higher occupancy of 58.07%. The company is aggressively expanding, with the Jamshedpur hospital on track for Q4 FY27 and a 7th facility in the works to take total capacity beyond 1,000 beds.
Confidence: HIGH
What changedThe company has demonstrated significant margin expansion and profit growth YoY, while progressing on its geographic diversification strategy beyond West Bengal.
Why it mattersThe sharp increase in PAT and margins indicates improving operational leverage and a successful shift toward high-value specialties like robotic surgeries and transplants, which command better realizations.
Q1 FY27 Total Income: ₹128.2 CrPAT Growth (YoY): 65.7%EBITDA Margin: 20.4%ARPOB: ₹42,350Current Bed Capacity: 719 bedsTarget Bed Capacity: >1,000 beds
📅 Short termThe stock is likely to react positively to the strong YoY earnings growth and margin expansion, reflecting improved operational efficiency.
📈 Long termThe structural shift toward a 1,000+ bed network and expansion into underserved markets like Raipur, Jamshedpur, and Ranchi provides a clear growth runway for the next 2-3 years.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Occupancy dilution from new facilities (currently 45.5% overall)
- Execution risks in commissioning the Jamshedpur and Ranchi projects
- Geographic concentration in Eastern India
Key Highlights
Total Income grew 18% YoY to ₹128.2 Cr, representing approximately 27% of the total FY26 revenue.
EBITDA increased 38.5% YoY to ₹26.2 Cr, with margins improving from 17.4% to 20.4%.
PAT surged 65.7% YoY to ₹12.7 Cr, despite a 12.6% sequential decline from Q4 FY26.
Raipur facility received a liver transplant license and is projected to reach breakeven by Q3 FY27.
Expansion plans are on track to increase total network capacity from 719 beds to over 1,000 beds.
👀 What to Watch
Investors should monitor the occupancy ramp-up at the Raipur facility and the timely commissioning of the Jamshedpur hospital in Q4 FY27. The ability to maintain 20%+ EBITDA margins as new capacity comes online will be a key performance indicator.
65.7% PAT Growth in Q1 FY27; GPT Healthcare Targets 1,000+ Beds in Two Years
GPT Healthcare reported a strong Q1 FY27 with revenue growing 17.8% YoY to ₹126.2 Cr. Profit After Tax (PAT) surged 65.7% YoY to ₹12.7 Cr, driven by an 11% improvement in ARPOB to ₹42,350 and higher clinical complexity. While overall occupancy stood at 45.5%, mature hospitals maintained 58.07% occupancy. The newly commissioned Raipur facility (158 beds) is on track for operational breakeven by Q3 FY27, supporting the company's roadmap to reach a 1,000-bed capacity by FY27-28.
Confidence: HIGH
What changedThe company has demonstrated significant margin recovery (20.4% vs 18.8% in FY26) as new capacities begin to stabilize and high-acuity procedures increase.
Why it mattersThe strong earnings growth indicates that the company is successfully absorbing the costs of its recent Raipur expansion while improving realizations at mature units through robotic and specialized care.
Q1 FY27 Revenue: ₹126.2 CrYoY PAT Growth: 65.7%ARPOB: ₹42,350Current Bed Capacity: 719 bedsMature Hospital Occupancy: 58.07%
📅 Short termThe stock may react positively to the sharp jump in PAT and EBITDA margins, reflecting improved operational efficiency.
📈 Long termThe structural growth story depends on the successful transition to a 1,000-bed network and reducing geographic concentration in West Bengal through the Raipur and Ranchi projects.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Low occupancy at Raipur (17.4%) remains a near-term drag on overall returns
- Geographic concentration in Eastern India
- Regulatory risks regarding price caps on medical procedures
Key Highlights
Revenue from operations increased 17.8% YoY to ₹126.2 Cr in Q1 FY27.
EBITDA grew 38.5% YoY to ₹26.2 Cr, with margins expanding to 20.4% from 17.4% in the previous year.
Average Revenue Per Occupied Bed (ARPOB) rose to ₹42,350, supported by 800+ cumulative robotic surgeries.
Raipur hospital contributed ₹10.6 Cr to revenue in Q1 FY27 despite a low 17.4% occupancy rate.
Company maintains a long-term ROCE target of approximately 25% through disciplined asset utilization.
👀 What to Watch
Investors should monitor the occupancy ramp-up at the Raipur facility and the execution timeline for the Ranchi hospital (planned for FY28) to validate the 1,000-bed expansion strategy.
GPTHEALTH Q1 FY27: PAT Jumps 65.7% YoY to ₹12.73 Cr on 17.8% Revenue Growth
GPT Healthcare reported a strong year-on-year performance for Q1 FY27, with revenue from operations growing 17.8% to ₹126.20 crore. Net profit surged 65.7% YoY to ₹12.73 crore, driven by improved operational efficiencies as total expenses grew at a slower rate (13.8%) than revenue. Sequentially, revenue remained flat compared to Q4 FY26, while PAT declined from ₹14.57 crore primarily due to a significant deferred tax credit in the preceding quarter. The company maintained healthy margins with EBITDA improving to approximately 20.7% from 17.6% in the same period last year.
Confidence: HIGH
What changedThe company reported its first-quarter results for FY27, demonstrating significant year-on-year margin expansion and profit growth despite flat sequential revenue.
Why it mattersThe strong YoY performance indicates successful scaling of existing operations and improved realizations (ARPOB), which is critical for a mid-sized hospital chain aiming to expand outside its core West Bengal market.
Revenue (Q1 FY27): ₹126.20 CrPAT (Q1 FY27): ₹12.73 CrYoY Revenue Growth: 17.8%YoY PAT Growth: 65.7%Q1 Revenue vs FY26 Revenue: 26.7%
📅 Short termThe stock is likely to react positively to the sharp jump in YoY profitability and margin improvement, reflecting better operational leverage.
📈 Long termStructural growth depends on the successful ramp-up of the Raipur unit and the execution of the Ranchi expansion to diversify geographic risk and increase bed capacity from the current 719 beds.
⚠ Risk flags
- Geographic concentration in Eastern India
- Potential regulatory price caps on medical procedures
- Increased competition from larger hospital chains entering West Bengal
Key Highlights
Revenue from operations increased 17.8% YoY to ₹126.20 crore from ₹107.11 crore.
Profit After Tax (PAT) grew 65.7% YoY to ₹12.73 crore compared to ₹7.68 crore in Q1 FY26.
Basic EPS for the quarter rose to ₹1.55 from ₹0.94 in the year-ago period.
Total expenses for the quarter stood at ₹111.07 crore, representing 88% of revenue vs 91% in Q1 FY26.
Other income grew 29.6% YoY to ₹2.03 crore.
👀 What to Watch
Monitor the occupancy levels at the newly commissioned Raipur facility, as the company targets a 13-14 month breakeven timeline. Investors should also track progress on the Ranchi hospital expansion planned for FY27-28 to reduce geographic concentration.
₹1.50 Final Dividend: GPT Healthcare Sets July 30 as Record Date for 37th AGM
GPT Healthcare has scheduled its 37th Annual General Meeting for August 6, 2026, and confirmed a final dividend of ₹1.50 per share (15% of face value) for FY25-26. The record date for dividend eligibility and e-voting is July 30, 2026, with payments to be completed by September 4, 2026. This dividend represents a payout of approximately 72% of the TTM EPS of ₹2.08. Investors can now access the full Annual Report for FY25-26 via the company's website.
Confidence: HIGH
What changedThe company has formalized the dates for its annual shareholder meeting and the record date for its final dividend payment.
Why it mattersThis is a routine but necessary administrative step that confirms the timing of cash returns to shareholders and provides the full financial disclosures for the previous fiscal year.
Final Dividend: ₹1.50 per shareDividend Yield: 0.95%Record Date: July 30, 2026AGM Date: August 6, 2026TTM EPS: ₹2.08
📅 Short termThe stock may see minor activity around the record date of July 30 as it trades ex-dividend.
📈 Long termLimited structural impact from this filing; long-term value depends on the successful ramp-up of the Raipur facility and the asset-light expansion in Ranchi by FY28.
Key Highlights
Final dividend of ₹1.50 per equity share (15% of ₹10 face value) announced for FY25-26.
Record date for dividend and e-voting eligibility set for July 30, 2026.
37th Annual General Meeting (AGM) scheduled for August 6, 2026, at 3:00 PM IST.
Dividend payment to be processed on or before September 4, 2026.
Annual Report for FY25-26 released, detailing the expansion to 719 beds from 561 beds.
👀 What to Watch
Investors should review the Annual Report for updates on the Raipur hospital's breakeven timeline and the Ranchi expansion project. Ensure bank details are linked to KYC-compliant folios by July 30 to receive the dividend.
GPT Healthcare sets Aug 6 for AGM; Final Dividend of ₹1.50 per share announced
GPT Healthcare has scheduled its 37th Annual General Meeting (AGM) for August 6, 2026. The company has proposed a final dividend of ₹1.50 per share (15% of face value), which, combined with the ₹1.00 interim dividend, brings the total FY26 payout to ₹2.50 per share. The record date for the final dividend is July 30, 2026, with payment to be completed by September 4, 2026. Additionally, the meeting will seek approval for remuneration increases for related-party medical professionals.
Confidence: HIGH
What changedThe company has formalized the timeline for its 37th AGM and the payment of its final dividend for FY26.
Why it mattersConfirms a total dividend yield of approximately 1.6% for the year and outlines management's intent to increase compensation for family members in key medical/administrative roles.
Final Dividend: ₹1.50 per shareTotal FY26 Dividend: ₹2.50 per shareDividend Yield (Approx): 1.6%Proposed VP Salary Ceiling: ₹10,00,000 per monthRecord Date: July 30, 2026
📅 Short termThe stock may see mild support leading up to the July 30 record date as investors position for the final dividend.
📈 Long termLimited structural impact from this routine filing; long-term value depends on the Raipur hospital breakeven and Ranchi expansion execution.
⚠ Risk flags
- Related-party transactions involving remuneration increases for promoter relatives
Key Highlights
Final dividend of ₹1.50 per equity share (15% on face value of ₹10) proposed for FY2025-26
Total dividend for the year reaches ₹2.50 per share including the ₹1.00 interim dividend already paid
Record date for dividend eligibility and e-voting cut-off set for July 30, 2026
Proposed salary hike for Dr. Mridul Tantia (VP) to ₹5,00,000 per month with a ceiling of ₹10,00,000
Minimum guarantee professional fee of ₹2,00,000 per month proposed for Dr. Niharika Tantia (Consultant)
👀 What to Watch
Investors should note the July 30 record date for dividend eligibility and monitor the AGM voting results regarding related-party remuneration approvals.
GPT Healthcare FY26 Revenue Grows 24% to ₹478.5 Cr; Raipur Hospital Ramp-up Underway
GPT Healthcare reported a 24% YoY revenue growth in Q4 FY26, reaching ₹128 crores, while full-year revenue stood at ₹478.5 crores. Mature hospitals delivered a strong EBITDA margin of 23.06%, though consolidated margins were diluted to 18.8% due to the newly commissioned Raipur facility's ₹13.8 crore EBITDA loss. Operational metrics showed improvement with ARPOB rising to ₹39,200 and network occupancy (excluding Raipur) at 55.9%. Management expects the Raipur facility to achieve operational breakeven by Q3 FY27 as occupancy continues to scale.
Key Highlights
Full-year FY26 revenue reached ₹478.5 crores with a consolidated PAT of ₹42.2 crores.
Mature hospital EBITDA margin improved by 94 basis points to 23.06% excluding the Raipur facility.
ARPOB increased from ₹37,000 to ₹39,200, driven by a better specialty mix and complex tertiary procedures.
Raipur Hospital reached 14.26% occupancy in Q4 FY26 and is targeted to break even by Q3 FY27.
Expansion remains on track with a 150-bed tertiary care hospital under development in Jamshedpur.
👀 What to Watch
Investors should focus on the margin expansion potential as the Raipur facility moves toward breakeven in late FY27. The strong performance of mature assets and the company's focus on underserved Eastern Indian markets support a positive long-term growth thesis.
GPT Healthcare Q4 Revenue Up 24.3% to ₹128 Cr; FY26 PAT Dips 15% on Expansion
GPT Healthcare reported a strong Q4 FY26 with revenue growing 24.3% YoY to ₹128 crore and PAT increasing 13% to ₹14.7 crore. However, full-year FY26 performance saw a 15.4% decline in PAT to ₹42.2 crore, primarily due to the commencement and gestation costs of the new Raipur facility. Operational metrics remain healthy with an ARPOB of ₹39,243 and occupancy at 55.9% for mature hospitals. The company is continuing its expansion strategy with a new 150-bed facility planned in Jamshedpur by FY27.
Key Highlights
Q4 Revenue grew 24.3% YoY to ₹128.0 Cr, while Q4 PAT rose 13% to ₹14.7 Cr.
Full-year FY26 Revenue increased 15.1% to ₹478.5 Cr, but PAT fell 15.4% to ₹42.2 Cr.
EBITDA margins for FY26 contracted to 18.84% from 22.10% in FY25 due to Raipur facility costs.
Operational ARPOB stood at ₹39,243 with 800+ robotic surgeries completed at Salt Lake.
Signed MoU for a new 150-bed hospital in Jamshedpur, targeted for FY27 completion.
👀 What to Watch
Investors should monitor the ramp-up of the Raipur facility and the execution of the Jamshedpur expansion, as these will drive future growth despite short-term margin pressure. The strong Q4 recovery suggests the business is successfully absorbing expansion costs.
GPT Healthcare FY26 Revenue Grows 15% to ₹478.5 Cr; Raipur Expansion Drags Margins
GPT Healthcare reported a 15.14% YoY revenue growth to ₹478.5 Cr for FY26, supported by a rise in ARPOB to ₹39,243. However, consolidated PAT declined by 15.43% to ₹42.2 Cr, largely due to the operational drag from the new Raipur hospital which incurred an EBITDA loss of ₹13.8 Cr. While mature hospitals maintained a strong EBITDA margin of 23.06%, the overall margin compressed to 18.84%. The company is continuing its expansion with a 150-bed Jamshedpur project to reach a total capacity of 869 beds.
Key Highlights
FY26 Revenue increased 15.14% YoY to ₹478.5 Cr, driven by improved clinical mix and ARPOB growth.
Mature hospitals delivered a resilient EBITDA of ₹103.9 Cr with a 23.06% margin.
New Raipur hospital impacted overall performance with an EBITDA loss of ₹13.8 Cr and low occupancy of 12.35%.
Overall network occupancy stood at 45.87%, but excluding Raipur, it remained healthy at 55.90%.
The 150-bed Jamshedpur tertiary care project is progressing as planned to expand regional footprint.
👀 What to Watch
Investors should focus on the occupancy ramp-up at the Raipur facility, as its path to breakeven is critical for overall margin recovery. While the core mature portfolio is performing well, short-term profitability will remain under pressure due to expansion-related depreciation and finance costs.
GPT Healthcare Recommends ₹1.50 Final Dividend for FY 2025-26
GPT Healthcare Limited has recommended a final dividend of ₹1.50 per equity share for the financial year ended March 31, 2026, which is 15% of the face value of ₹10. The dividend is subject to shareholder approval at the 37th Annual General Meeting (AGM) scheduled for August 6, 2026. The company has established July 30, 2026, as the record date for determining dividend eligibility. If approved, the payout will be completed within 30 days from the date of the AGM.
Key Highlights
Recommended a final dividend of ₹1.50 per equity share (15% payout on ₹10 face value)
Record date for dividend entitlement is fixed as July 30, 2026
37th Annual General Meeting (AGM) scheduled for August 6, 2026
Book closure period set from July 31, 2026, to August 6, 2026
Dividend to be paid within 30 days of shareholder approval
👀 What to Watch
Investors seeking dividend income should ensure they hold the stock before the record date of July 30, 2026. The 15% dividend payout indicates a healthy cash flow and a commitment to shareholder returns.
GPT Healthcare Recommends ₹1.50 Final Dividend; Sets July 30 as Record Date
GPT Healthcare's Board has recommended a final dividend of ₹1.50 per equity share (15% of face value) for the financial year 2025-26. The company has fixed July 30, 2026, as the record date to determine shareholder eligibility for this payout. The dividend is subject to shareholder approval at the upcoming 37th Annual General Meeting scheduled for August 6, 2026. If approved, the payment will be processed within 30 days of the AGM declaration.
Key Highlights
Recommended a final dividend of ₹1.50 per share, representing 15% of the ₹10 face value.
Fixed July 30, 2026, as the record date for determining dividend entitlement.
The 37th Annual General Meeting (AGM) is scheduled for August 6, 2026, via video conferencing.
Book closure period is set from July 31, 2026, to August 6, 2026, for AGM purposes.
👀 What to Watch
Investors interested in the dividend should ensure they hold the stock before the ex-dividend date, which typically precedes the July 30 record date. Monitor the AGM outcome on August 6 for final approval of the payout.
GPT Healthcare Approves FY26 Results, Recommends ₹1.50 Final Dividend
GPT Healthcare Limited has approved its audited financial results for the fiscal year ended March 31, 2026, with the statutory auditor issuing an unmodified opinion. The Board has recommended a final dividend of 15% (₹1.50 per share), with a record date set for July 30, 2026. Key management decisions include the re-appointment of two independent directors for a second five-year term and the continuation of a non-executive director beyond the age of 75. The company also approved remuneration increases for certain related-party roles, subject to shareholder approval at the upcoming AGM on August 6, 2026.
Key Highlights
Recommended a final dividend of 15% or ₹1.50 per equity share for FY 2025-26.
Set July 30, 2026, as the record date for dividend entitlement and the 37th Annual General Meeting.
Statutory Auditors S R Batliboi & Co LLP issued an unmodified opinion on the FY26 financial results.
Re-appointed Independent Directors Mr. Hari Modi and Dr. Tapti Sen for a second 5-year term starting September 2026.
Approved remuneration increases for related parties Dr. Mridul Tantia and Dr. Niharika Tantia, pending shareholder approval.
👀 What to Watch
Investors should ensure they hold shares by the July 30, 2026, record date to qualify for the ₹1.50 dividend. The clean audit report and management continuity suggest operational stability, though investors should review the detailed financial statements for margin performance.
GPT Healthcare Q3 FY26: Revenue Grows 16.8% YoY; Raipur Facility Nears EBITDA Breakeven
GPT Healthcare reported a 12.12% YoY revenue growth for 9M FY26, reaching ₹350.5 crores, with EBITDA margins stable at 18.58%. The company is seeing steady operational improvements, with occupancy (excluding the new Raipur facility) rising to 55% and ARPOB standing at ₹38,797. A key highlight is the Raipur facility, which reduced its quarterly EBITDA loss to ₹2.5 crores and is expected to break even within the next six months. Management remains committed to expanding its capacity to 1,000 beds by 2027, with the Jamshedpur project currently on track.
Key Highlights
9M FY26 Revenue grew 12.12% YoY to ₹350.5 crores, while Q3 revenue surged 16.81% YoY.
EBITDA for 9M FY26 stood at ₹65.1 crores with an 18.58% margin; PAT was ₹27.6 crores.
Raipur facility EBITDA loss narrowed to ₹2.5 crores in Q3, with monthly breakeven expected in 6 months.
Salt Lake hospital occupancy improved to 63%, supported by over 750 robotic-enabled surgical procedures.
Company on track to reach 1,000-bed capacity by 2027, including the upcoming 150-bed Jamshedpur facility.
👀 What to Watch
Investors should monitor the Raipur facility's path to profitability over the next two quarters as it will significantly boost overall margins. The company remains a strong growth play in the underserved Eastern India healthcare market.
GPT Healthcare Q3 Revenue Up 17% to ₹122 Cr; PAT Declines 23.5% Amid Margin Pressure
GPT Healthcare reported a 16.81% YoY increase in Q3 FY26 revenue to ₹121.6 crore, supported by higher patient volumes and a stronger specialty mix. However, the company faced significant margin contraction, with EBITDA margins falling to 18.20% from 22.23% in the previous year's quarter. Consequently, Profit After Tax (PAT) for Q3 FY26 declined by 23.5% YoY to ₹9.4 crore. For the nine-month period (9M FY26), revenue grew 12.12% to ₹350.5 crore, while PAT fell 25.32% to ₹27.6 crore, reflecting the impact of scaling new facilities like Raipur.
Key Highlights
Q3 FY26 Total Revenue grew 16.81% YoY to ₹121.6 crore, while 9M FY26 revenue rose 12.12% to ₹350.5 crore.
Profit After Tax (PAT) for Q3 FY26 declined 23.5% YoY to ₹9.4 crore from ₹12.1 crore.
EBITDA margins contracted to 18.20% in Q3 FY26 compared to 22.23% in the corresponding quarter last year.
Average Revenue Per Occupied Bed (ARPOB) for 9M FY26 stood at ₹38,797 with an overall occupancy of 45%.
Company completed 750+ robotic surgeries at ILS Salt Lake and commissioned CTVS at ILS-Dum Dum.
👀 What to Watch
Investors should be cautious as the sharp decline in profitability and margins may weigh on the stock price in the short term. Monitor the ramp-up of the Raipur facility and the progress of the Jamshedpur project to see if operating leverage improves margins in future quarters.
GPT Healthcare Q3 Revenue Grows 16.8% to ₹121.6 Cr; PAT Declines 23.5% on Expansion Costs
GPT Healthcare reported a 16.8% YoY revenue growth in Q3 FY26, reaching ₹121.6 Cr, supported by a 6% increase in ARPOB to ₹38,797. However, profitability faced headwinds due to the commissioning of the new Raipur facility, leading to a 23.5% YoY decline in Q3 PAT to ₹9.4 Cr. While overall network occupancy was 45%, mature hospitals showed resilience with occupancy improving marginally to 55%. The company remains focused on its 1,000-bed target by 2027, with the 150-bed Jamshedpur project currently in the planning phase.
Key Highlights
Revenue for 9M FY26 increased 12.1% YoY to ₹350.5 Cr, while Q3 revenue rose 16.8% to ₹121.6 Cr.
Q3 EBITDA margin contracted to 18.2% from 22.2% YoY, with PAT falling 23.5% to ₹9.4 Cr.
ARPOB grew 6% YoY to ₹38,797, reflecting strengthened clinical offerings and specialty mix.
Raipur facility (158 beds) is scaling up after commissioning in Q1 FY26, impacting current margins.
Successfully performed 750+ robotic surgeries and launched CTVS services at the Dum Dum facility.
👀 What to Watch
Investors should monitor the ramp-up and break-even timeline of the Raipur hospital, as its initial losses are currently weighing on consolidated margins. The long-term investment thesis remains intact based on the company's aggressive expansion toward a 1,000-bed capacity in the underserved Eastern India market.
GPT Healthcare Q3FY26 Revenue up 17.5% YoY to ₹120 Cr; PAT drops 23.5% to ₹9.37 Cr
GPT Healthcare reported a 17.5% YoY growth in revenue from operations to ₹120.16 crore for Q3FY26. However, net profit declined significantly by 23.5% YoY to ₹9.37 crore, primarily due to a sharp rise in operating and depreciation expenses. On a nine-month basis, while revenue grew to ₹346.18 crore, profit after tax fell from ₹37.03 crore to ₹27.65 crore. The company's margins were pressured by a 29% YoY increase in other expenses and a 52% jump in depreciation costs.
Key Highlights
Revenue from operations grew 17.5% YoY to ₹12,015.81 lakhs in Q3FY26.
Net Profit (PAT) declined by 23.5% YoY to ₹936.83 lakhs from ₹1,224.61 lakhs in the same quarter last year.
Other expenses surged 28.9% YoY to ₹5,448.77 lakhs, significantly impacting operating margins.
Depreciation and amortization expenses increased by 52.3% YoY to ₹710.99 lakhs.
Nine-month (9MFY26) PAT stands at ₹2,765.45 lakhs, down 25.3% compared to ₹3,703.17 lakhs in 9MFY25.
👀 What to Watch
Investors should exercise caution as the company is experiencing significant margin compression despite healthy top-line growth. It is critical to monitor management's explanation for the surge in 'Other expenses' and the impact of new capacity on depreciation.
